Shares of Sientra hit a new all-time low on Oct. 16 when the stock fell another six cents on the day and closed at $5.77 per share. For the Goleta-based breast implant manufacturer, it marks another low in a saga that’s starting to turn ugly. Shares of Sientra initially plummeted from $20.58 per share to Read More →
Sientra CEO Hani Zeini sent another letter to plastic surgeons to reassure them that its products are safe. Sientra, a Goleta-based breast implant manufacturer, saw shares drop sharply over the past few months from a high of $23.75 on July 23. In recent weeks the stock fell from $20.58 on Sept. 23 to a close Read More →
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
The Food and Drug Administration approved Amgen’s Kyprolis for second-line treatments of multiple-myeloma on Friday. Thousand Oaks-based Amgen’s new treatment for multiple-myeloma could pay off big for the company now that the treatment can be accessed by more patients in the second line of treatments. Kyprolis was approved for third-line treatments in 2012. The FDA’s Read More →
Thousand Oaks-based Amgen announced Thursday that it submitted data comparing its new multiple-myeloma drug against a rival to the Food and Drug Administration. Kyprolis is Amgen’s new treatment for multiple-myeloma, which is a form of blood cancer that forms in plasma cells and typically grows in bone marrow. The drug was approved for third-line treatments Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
After nearly eight years of tangling with the Food and Drug Administration, San Luis Obipso-based FzioMed said it might receive approval to sell its products in the U.S. by year’s end.
